Effects of Nasal Ventilation on Cerebral and Pulmonary Function in Orally Intubated Patients

RecruitingOBSERVATIONAL
Enrollment

22

Participants

Timeline

Start Date

January 31, 2025

Primary Completion Date

January 31, 2026

Study Completion Date

February 1, 2026

Conditions
Hypoxemic Acute Respiratory Failure
Interventions
DEVICE

EEG activity measurement

"The nasal ventilation device (placed as part of the research) (AIRVO 2; Fisher and Paykel Healthcare, Auckland, New Zealand) will be positioned via nasal cannulas adapted to the patient's anatomy. The FiO2 will be set at 21% and the flow rate will be fixed at 0 L/min at the inclusion visit. The temperature of the humidified nasal oxygenator will be set at 31°C.~Six 30-minute experimental conditions will be performed successively: 1) 0 L/min flow, FiO2 21%, 2) 30 L/min flow, FiO2 21%, 3) 30 L/min flow, FiO2 100%, 4) 60 L/min flow, FiO2 21%, 5) 60 L/min flow, FiO2 100%, 6) Negative control.~At the end of each condition, a 10-minute thoracic electrical impedance tomography recording, a 10-minute EEG recording, a 10-minute cerebral NIRS recording and an instantaneous temporal Doppler velocity measurement will be performed. A blood gas (1.5 mL) will also be taken at the end of each condition."

Trial Locations (1)

75013

RECRUITING

Service de Médecine Intensive Réanimation - Hôpital Pitié -Salpêtrière, Paris

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER